137 related articles for article (PubMed ID: 37347260)
41. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
[TBL] [Abstract][Full Text] [Related]
42. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P
Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of pathogenetic mutations in breast cancer predisposition genes in population-based studies conducted among Chinese women.
Zeng C; Guo X; Wen W; Shi J; Long J; Cai Q; Shu XO; Xiang Y; Zheng W
Breast Cancer Res Treat; 2020 Jun; 181(2):465-473. PubMed ID: 32318955
[TBL] [Abstract][Full Text] [Related]
44. Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
Vysotskaia V; Kaseniit KE; Bucheit L; Ready K; Price K; Johansen Taber K
Cancer; 2020 Feb; 126(3):549-558. PubMed ID: 31682005
[TBL] [Abstract][Full Text] [Related]
45. Genetic testing results in Slovenian male breast cancer cohort indicate the BRCA2 7806-2A > G founder variant could be associated with higher male breast cancer risk.
Strojnik K; Krajc M; Dragos VS; Stegel V; Novakovic S; Blatnik A
Breast Cancer Res Treat; 2021 Aug; 188(3):811-820. PubMed ID: 33891299
[TBL] [Abstract][Full Text] [Related]
46. Men at risk of being a mutation carrier for hereditary breast/ovarian cancer: an exploration of attitudes and psychological functioning during genetic testing.
Lodder L; Frets PG; Trijsburg RW; Tibben A; Meijers-Heijboer EJ; Duivenvoorden HJ; Wagner A; van Der Meer CA; Devilee P; Cornelisse CJ; Niermeijer MF
Eur J Hum Genet; 2001 Jul; 9(7):492-500. PubMed ID: 11464240
[TBL] [Abstract][Full Text] [Related]
47. Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations.
Tsaousis GN; Papadopoulou E; Apessos A; Agiannitopoulos K; Pepe G; Kampouri S; Diamantopoulos N; Floros T; Iosifidou R; Katopodi O; Koumarianou A; Markopoulos C; Papazisis K; Venizelos V; Xanthakis I; Xepapadakis G; Banu E; Eniu DT; Negru S; Stanculeanu DL; Ungureanu A; Ozmen V; Tansan S; Tekinel M; Yalcin S; Nasioulas G
BMC Cancer; 2019 Jun; 19(1):535. PubMed ID: 31159747
[TBL] [Abstract][Full Text] [Related]
48. Germline molecular data in hereditary breast cancer in Brazil: Lessons from a large single-center analysis.
Sandoval RL; Leite ACR; Barbalho DM; Assad DX; Barroso R; Polidorio N; Dos Anjos CH; de Miranda AD; Ferreira ACSM; Fernandes GDS; Achatz MI
PLoS One; 2021; 16(2):e0247363. PubMed ID: 33606809
[TBL] [Abstract][Full Text] [Related]
49. Screening of over 1000 Indian patients with breast and/or ovarian cancer with a multi-gene panel: prevalence of BRCA1/2 and non-BRCA mutations.
Singh J; Thota N; Singh S; Padhi S; Mohan P; Deshwal S; Sur S; Ghosh M; Agarwal A; Sarin R; Ahmed R; Almel S; Chakraborti B; Raina V; DadiReddy PK; Smruti BK; Rajappa S; Dodagoudar C; Aggarwal S; Singhal M; Joshi A; Kumar R; Kumar A; Mishra DK; Arora N; Karaba A; Sankaran S; Katragadda S; Ghosh A; Veeramachaneni V; Hariharan R; Mannan AU
Breast Cancer Res Treat; 2018 Jul; 170(1):189-196. PubMed ID: 29470806
[TBL] [Abstract][Full Text] [Related]
50. Gynecological-endocrinological aspects in women carriers of BRCA1/2 gene mutations.
Doren A; Vecchiola A; Aguirre B; Villaseca P
Climacteric; 2018 Dec; 21(6):529-535. PubMed ID: 30295091
[TBL] [Abstract][Full Text] [Related]
51. Hereditary Ovarian Cancer and Risk Reduction.
Andrews L; Mutch DG
Best Pract Res Clin Obstet Gynaecol; 2017 May; 41():31-48. PubMed ID: 28254144
[TBL] [Abstract][Full Text] [Related]
52. Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic.
Riedlova P; Janoutova J; Hermanova B
Mol Biol Rep; 2020 Apr; 47(4):2763-2769. PubMed ID: 32180084
[TBL] [Abstract][Full Text] [Related]
53. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
Demir S; Tozkir H; Gurkan H; Atli EI; Yalcintepe S; Atli E; Sezer YA; Eker D; Tuncbilek N; Tastekin E; Ozen Y; Cicin I
J BUON; 2020; 25(3):1337-1347. PubMed ID: 32862574
[TBL] [Abstract][Full Text] [Related]
54. RAD51C mutation screening in high-risk patients from Serbian hereditary breast/ovarian cancer families.
Krivokuca A; Yanowski K; Rakobradovic J; Benitez J; Brankovic-Magic M
Cancer Biomark; 2015; 15(6):775-81. PubMed ID: 26406419
[TBL] [Abstract][Full Text] [Related]
55. Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D.
Graffeo R; Rana HQ; Conforti F; Bonanni B; Cardoso MJ; Paluch-Shimon S; Pagani O; Goldhirsch A; Partridge AH; Lambertini M; Garber JE
Breast; 2022 Oct; 65():32-40. PubMed ID: 35772246
[TBL] [Abstract][Full Text] [Related]
56. Genetic testing for hereditary predisposition to breast cancer in the real world: Initial experience.
da Silva Fontinele DR; Assunção Ribeiro da Costa RE; da Silva Magalhães MK; Vieira SC
Breast Dis; 2022; 41(1):249-254. PubMed ID: 35570472
[TBL] [Abstract][Full Text] [Related]
57. Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer.
Machackova E; Foretova L; Lukesova M; Vasickova P; Navratilova M; Coene I; Pavlu H; Kosinova V; Kuklova J; Claes K
BMC Cancer; 2008 May; 8():140. PubMed ID: 18489799
[TBL] [Abstract][Full Text] [Related]
58. Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics. European Familial Breast Cancer Collaborative Group.
Vasen HF; Haites NE; Evans DG; Steel CM; Møller P; Hodgson S; Eccles D; Morrison P; Stoppa Lyonet D; Chang-Claude J; Caligo M
Eur J Cancer; 1998 Nov; 34(12):1922-6. PubMed ID: 10023316
[TBL] [Abstract][Full Text] [Related]
59. The counselees' self-reported request for psychological help in genetic counseling for hereditary breast/ovarian cancer: not only psychopathology matters.
Vos J; van Asperen CJ; Oosterwijk JC; Menko FH; Collee MJ; Gomez Garcia E; Tibben A
Psychooncology; 2013 Apr; 22(4):902-10. PubMed ID: 22740372
[TBL] [Abstract][Full Text] [Related]
60. Family planning in carriers of BRCA1 and BRCA2 pathogenic variants.
Haddad JM; Robison K; Beffa L; Laprise J; ScaliaWilbur J; Raker CA; Clark MA; Hofstatter E; Dalela D; Brown A; Bradford L; Toland M; Stuckey A
J Genet Couns; 2021 Dec; 30(6):1570-1581. PubMed ID: 33904624
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]